Additional file 5 OPA, PPA, and NPA between PD-L1 assays in invasive UC samples (*N*=255)

|  |  |  |
| --- | --- | --- |
| **Clinical algorithm** | **Comparator assay** | **VENTANA SP263 (TC/IC 25%) assay used as reference,** **% agreement (95% CI)** a |
| **OPA** | **PPA** | **NPA** |
| TC or ICICArea ≥25%(VENTANA SP263) | PD-L1 IHC 22C3 pharmDX | 92.5% (89.3%) | 88.1% (81.5%) | 95.5% (91.6%) |
| PD-L1 IHC 28-8 pharmDX | 90.2% (86.6%) | 80.2% (72.5%) | 96.8% (93.3%) |
| VENTANA SP142 | 83.5% (79.2%) | 64.4% (55.8%) | 96.1% (92.5%) |
| CPS ≥1(PD-L1 IHC 22C3 pharmDX) | PD-L1 IHC 22C3 pharmDX | 76.9% (72.1%) | 93.1% (87.4%) | 66.2% (59.4%) |
| CPS ≥10(PD-L1 IHC 22C3 pharmDX)  | PD-L1 IHC 22C3 pharmDX | 82.0% (77.5%) | 69.3% (60.9%) | 90.3% (85.4%) |
| TC ≥1%(PD-L1 IHC 28-8 pharmDX) | PD-L1 IHC 28-8 pharmDX | 75.7% (70.9%) | 72.3% (64.0%) | 77.9% (71.7%) |
| ICTumorArea ≥5%(VENTANA SP142) | VENTANA SP142 | 66.3% (61.1%) | 15.8% (10.2%) | 99.4% (97.0%) |